^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR exon 19 mutation

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
    Entrez ID:
    1956
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    9ms
    Comprehensive molecular and clinical insights into non-small cell lung cancer transformation to small cell lung cancer with an illustrative case report. (PubMed, J Drug Target)
    A small number of documented cases of tSCLC after immunotherapy highlight the need for rebiopsies at progression to diagnose this potential resistance mechanism. Further research is needed to better understand the mechanisms underlying this phenomenon and to develop more effective treatment strategies for patients with tSCLC.
    Review • Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 19 mutation • EGFR positive
    1year
    An in vitro model and the underlying pathways of sinonasal inverted papilloma development. (PubMed, Sci Rep)
    These results suggest that specific mutations in EGFR exon 20 play a crucial role in SIP development, partially though hyper-activation of the PI3K/AKT and MAPK signaling pathways. This study presents the first in vitro model for SIP development, which could facilitate further investigations into SIP pathogenesis and preclinical studies for new therapeutic agents.
    Preclinical • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR expression • EGFR exon 19 mutation • EGFR exon 20 mutation • EGFR E746 • EGFR S768_D770dup
    over1year
    RIGHT VENTRICULAR OUTFLOW TRACT OBSTRUCTION SECONDARY TO METASTATIC PULMONARY ADENOCARCINOMA (CHEST 2023)
    She had a recent diagnosis of pulmonary embolism treated with apixaban... RVOTO from tumor mass effect should be on the differential of patients with metastatic primary lung cancer presenting with new orthostatic signs and symptoms.
    Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 19 mutation
    2years
    Molecular Divergence upon EGFR-TKI Resistance Could Be Dependent on the Exon Location of the Original EGFR-Sensitizing Mutation. (PubMed, Cancers (Basel))
    Similarly, mutations in NRAS and HRAS were more frequently detected in samples from tumors harboring mutations in exons 18 or 21 (Fisher p-value: 0.050 and Fisher p-value: 0.099, respectively). In conclusion, our data suggest that the mechanisms underlying EGFR-TKI resistance could be dependent on the exon location of the original EGFR-sensitizing mutation.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • FGFR3 (Fibroblast growth factor receptor 3) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    TP53 mutation • KRAS mutation • EGFR mutation • NRAS mutation • EGFR T790M • EGFR exon 19 mutation • HRAS mutation • EGFR positive • EGFR exon 18 mutation
    |
    Oncomine™ Pan-Cancer Cell-Free Assay
    over2years
    Use of thyroid transcription factor 1 and napsin A to predict local failure and survival after Gamma Knife radiosurgery in patients with brain metastases from lung adenocarcinoma. (PubMed, J Neurosurg)
    Pathological biomarkers of primary cancer should be considered to predict clinical outcomes after SRS in patients with lung ADC. Use of such biomarkers may help to provide personalized treatment to each patient, improving clinical outcomes after SRS.
    Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • NKX2-1 (NK2 Homeobox 1) • NAPSA (Napsin A Aspartic Peptidase)
    |
    EGFR mutation • EGFR exon 21 mutation • EGFR exon 19 mutation
    over2years
    Clinical and Radiological Characteristics to Differentiate Between EGFR Exon 21 and Exon 19 Mutations in Patients With Lung Adenocarcinoma: A Systematic Literature Review and Meta-Analysis. (PubMed, Cureus)
    Specific EGFR exon 21 and 19 mutations cannot be differentiated through characteristics (absence of smoking status and female sex) or radiological patterns (GGO, air bronchogram, pleural retraction, and speculation). There is limited data to assess if early disease stage or vascular convergence aids in differentiating exon 21 from 19 mutations in patients with lung adenocarcinoma.
    Retrospective data • Review • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 19 mutation
    3years
    The pathological tissue expression pattern and clinical significance of m6A-regulatory genes in non-small cell lung cancer. (PubMed, J Gene Med)
    Our results indicate that m6A regulators, including METTL3, ALKBH5, YTHDC2, and YTHDF1, could serve as predictive markers of NSCLC, which will facilitate early detection and diagnosis of NSCLC.
    Clinical • Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • ALKBH5 (AlkB Homolog 5, RNA Demethylase) • METTL3 (Methyltransferase Like 3)
    |
    TP53 mutation • KRAS mutation • EGFR mutation • EGFR exon 19 mutation
    3years
    Gastric metastasis and transformation of primary lung adenocarcinoma to small cell cancer after acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors: A case report. (PubMed, Medicine (Baltimore))
    Timely second biopsies should be considered in the diagnosis of phenotypic transformation. After transformation, chemotherapeutic treatment with etoposide and platinum and maintenance therapy with osimertinib inhibited the progression of the disease.
    Clinical • Preclinical • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M • EGFR exon 19 mutation
    |
    Tagrisso (osimertinib) • gefitinib • etoposide IV
    over3years
    [VIRTUAL] Spectrum of Resistance Mechanisms to First, Second and Third Generation Tyrosine Kinase Inhibitors in EGFR Mutant NSCLC Patients (IASLC-WCLC 2021)
    Other mutations detected were CTNNB1 D32N, KRAS G12V, and PIK3CA E542K Conclusion Resistance development is unavoidable in EGFR mutant advanced NSCLC on any generation of TKIs. NGS offers an advantage in diagnosing mechanism of resistance for further choice of therapy.
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MET (MET proto-oncogene, receptor tyrosine kinase) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    |
    TP53 mutation • KRAS mutation • EGFR mutation • KRAS G12C • BRAF mutation • PIK3CA mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR T790M • EGFR amplification • EGFR exon 20 insertion • PIK3CA H1047R • KRAS G12V • EGFR C797S • EGFR exon 19 mutation • MET mutation • EGFR exon 19 deletion + EGFR T790M • KRAS G12 • PIK3CA E542K • ALK translocation • EGFR exon 20 mutation • KRAS G13 • BRAF G469A • PIK3CA E542 • KRAS G13C • EGFR H835L • EGFR L833V • PIK3CA exon 9 mutation + HR positive • EGFR E709A • TP53 R213
    |
    Oncomine Focus Assay
    over3years
    TP53 mutations in circulating tumor DNA in advanced epidermal growth factor receptor-mutant lung adenocarcinoma patients treated with gefitinib. (PubMed, Transl Oncol)
    Patients with TP53 mutations, especially in exons 6 and 7, had a lower response rate and shorter PFS and OS when treated with gefitinib. Moreover, TP53 exon 5 mutation divided TP53 mutations in disruptive and non-disruptive types.
    Clinical • Journal • Circulating tumor DNA
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53)
    |
    TP53 mutation • EGFR mutation • EGFR L858R • EGFR exon 19 mutation • TP53 exon 5 mutation
    |
    gefitinib
    over3years
    [VIRTUAL] Primary and secondary resistance mechanisms in first, second and third generation tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer patients. (ASCO 2021)
    Primary and secondary acquired resistance is unavoidable in EGFR mutant advanced NSCLC on any generation of TKIs . NGS offers an advantage in diagnosing mechanism of resistance for further choice of therapy.
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MET (MET proto-oncogene, receptor tyrosine kinase) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    |
    TP53 mutation • KRAS mutation • EGFR mutation • KRAS G12C • BRAF mutation • PIK3CA mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR T790M • EGFR amplification • EGFR exon 20 insertion • PIK3CA H1047R • KRAS G12V • EGFR C797S • EGFR exon 19 mutation • MET mutation • EGFR exon 19 deletion + EGFR T790M • KRAS G12 • PIK3CA E542K • ALK translocation • EGFR exon 20 mutation • KRAS G13 • BRAF G469A • PIK3CA E542 • KRAS G13C • PIK3CA exon 9 mutation + HR positive • EGFR E709A • TP53 R213
    |
    Oncomine Focus Assay
    4years
    [VIRTUAL] Real-World Characteristics and Outcomes of Advanced NSCLC Patients with Exon 19 or 21 EGFR Mutations (IASLC-NACLC 2020)
    "In real-world clinical practice, patients with an EGFR exon 19 mutation have a prognostic advantage over Exon 21 with statistically better rwPFS and rwPFS2. Further research is needed to examine the unmet need and optimal treatment options for these exon 21 patients."
    Real-world evidence • Clinical
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 21 mutation • EGFR exon 19 mutation
    |
    FoundationOne® CDx
    over4years
    The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma. (PubMed, Clin Cancer Res)
    These results highlight important differences between specific Ex19Del mutations that may be relevant for optimizing TKI choice for patients.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 19 deletion • EGFR exon 19 mutation • EGFR E746
    |
    Tagrisso (osimertinib) • erlotinib • Gilotrif (afatinib)
    over4years
    The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma-Letter. (PubMed, Clin Cancer Res)
    No abstract available
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 19 mutation
    over4years
    Effectiveness of osimertinib in patients with lung adenocarcinoma in clinical practice - the Expanded Drug Access Program in Poland. (PubMed, Adv Respir Med)
    These results confirm the value of osimertinib in patients with previously treated EGFR T790M-mutant NSCLC. Clinical benefit was evident in patients with cerebral metastases and moderate performance status.
    Clinical • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M • EGFR exon 21 mutation • EGFR exon 19 mutation
    |
    Tagrisso (osimertinib)
    over4years
    Heterogeneous Response to First-Generation Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers with Different EGFR Exon 19 Mutations. (PubMed, Target Oncol)
    Deletion location and type variants (with or without an insertion and/or a substitution) might affect first-generation TKI efficacy, and different EGFR exon 19dels should be considered when making decisions on which EGFR TKI should be used.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 19 deletion • EGFR T790M • EGFR exon 19 mutation • EGFR T790M + exon 19 deletion
    over4years
    [VIRTUAL] Improvement in quality and length of life following treatment with mifepristone in women with stage IV non-small cell lung cancer, positive for the epidermal growth factor receptor (EGFR) mutation, that previously progressed on targeted therapy (AACR-II 2020)
    The brain metastasis was treated with palliative radiation therapy and erlotinib was started...She then had a second course of brain radiation and 5 months after stopping afatinib she began osimertinib...More importantly they both feel much better, with no dyspnea, or pain, and remain ECOG-0. Thus, similar to small cell lung cancer and NSCLC devoid of tumor markers, or with the PD-L1 mutation, patients with advanced NSCLC with EGFR mutation also seem to respond to the progesterone receptor modulator, mifepristone.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • PGR (Progesterone receptor)
    |
    EGFR mutation • EGFR exon 19 mutation • EGFR positive • PD-L1 mutation
    |
    Tagrisso (osimertinib) • erlotinib • Gilotrif (afatinib) • Mifeprex (mifepristone)